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Abstract
Background: Cystic Fibrosis (CF) is an autosomal recessive disease that affects the function of a number of organs,
principally the lungs, but also the gastrointestinal tract. The manifestations of cystic fibrosis transmembrane conductance
regulator (CFTR) dysfunction in the gastrointestinal tract, as well as frequent antibiotic exposure, undoubtedly disrupts the
gut microbiota. To analyse the effects of CF and its management on the microbiome, we compared the gut microbiota
of 43 individuals with CF during a period of stability, to that of 69 non-CF controls using 454-pyrosequencing of the 16S
rRNA gene. The impact of clinical parameters, including antibiotic therapy, on the results was also assessed.
Results: The CF-associated microbiome had reduced microbial diversity, an increase in Firmicutes and a reduction in
Bacteroidetes compared to the non-CF controls. While the greatest number of differences in taxonomic abundances of the
intestinal microbiota was observed between individuals with CF and the healthy controls, gut microbiota differences were
also reported between people with CF when grouped by clinical parameters including % predicted FEV1 (measure of lung
dysfunction) and the number of intravenous (IV) antibiotic courses in the previous 12 months. Notably, CF individuals
presenting with severe lung dysfunction (% predicted FEV1≤ 40%) had significantly (p < 0.05) reduced gut microbiota
diversity relative to those presenting with mild or moderate dysfunction. A significant negative correlation (−0.383,
Simpson’s Diversity Index) was also observed between the number of IV antibiotic courses and gut microbiota diversity.
Conclusions: This is one of the largest single-centre studies on gut microbiota in stable adults with CF and demonstrates
the significantly altered gut microbiota, including reduced microbial diversity seen in CF patients compared to healthy
controls. The data show the impact that CF and it's management have on gut microbiota, presenting the opportunity to
develop CF specific probiotics to minimise microbiota alterations.
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Background
The healthy human gut is populated with in excess of
1011 microbes per millilitre of luminal content [1]. This
population is generally stable over time in healthy adults,
however, alteration of the normal gut microbiota has
been seen in a number of diseases/conditions, including
diabetes, obesity, irritable bowel syndrome, and inflam-
matory bowel disease [2–6]. More recently, it has been
shown that those with cystic fibrosis (CF) also exhibit an
altered gut microbiota, compared to healthy controls [7].
CF is the most common life shortening autosomal
recessive disease. It is caused by a mutation in the cystic
fibrosis transmembrane conductance regulator (CFTR)
gene, which results in expression of dysfunctional Cl− ion
transport proteins in epithelial cells. This causes inadequate
hydration in the lumen of tubular organs, resulting in vis-
cous mucus accumulating along a variety of epithelial sur-
faces, including the lungs and gastrointestinal tract [8]. CF
results in a range of gastrointestinal complications includ-
ing pancreatic insufficiency (PI), slowed intestinal transit,
malabsorption and obstruction [9–14]. Progressive pul-
monary disease due to chronic and recurrent infection is
the number one cause of death in people with CF [15].
Consequently, people with CF are frequently treated with
broad spectrum antibiotics [16, 17]. Previous studies in
non-CF individuals have shown that antibiotic therapy
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reduces the diversity of the intestinal microbiota, as well as
altering the relative abundances of susceptible bacterial spe-
cies [18, 19]. While the intestinal microbiota has been
shown to return to a normal pre-treatment state within
weeks of cessation of antibiotic therapy, it has been noted
that some taxonomic changes can persist for long periods
after antibiotic treatment [19–22]. Frequent courses of anti-
biotics are also likely to increase the risk of developing anti-
biotic resistant strains, as well as reducing the hosts’
colonization resistance allowing bacteria to establish, in-
creasing the risk of proliferation of opportunistic patho-
gens, including Clostridium difficile [23, 24]. Research on
the impact of CF on gut microbiota has increased in recent
years. Previous investigations revealed that children with
CF had lower species diversity and lower temporal stability
in their gut microbiota relative to non-CF sibling controls
[25]. Frequent antibiotic therapy to treat pulmonary infec-
tions, in addition to the inherent effect of CFTR dysfunc-
tion on the gastrointestinal tract, have been proposed as
possible causes of this altered gut microbiota of people
with CF [25]. This theory is supported by studies in mur-
ine models of CF that have demonstrated decreased rich-
ness, evenness, and diversity of the small intestinal
microbiota relative to non-CF mice [26]. A study examin-
ing the development of the gut and lung microbiome in
children with CF, revealed both microbial communities
develop simultaneously and share a number of colonising
species [27]. It was also revealed that the appearance of
some species in the gut can presage their appearance in
the lungs, suggesting the gut microbiota may help shape
the development of the lung microbiota. This coupled
with the success of probiotic trials at reducing gastrointes-
tinal inflammation and exacerbation frequency in people
with CF [10, 28, 29], highlights the importance of under-
standing the CF gut microbiota and the effect of disease
manifestation and its treatment on this ecosystem.
To date, studies investigating the CF gut microbiota
have varied in approach adopting both culture-
dependent and culture-independent approaches in either
children with CF [25, 30] or CF animal models [26, 31].
In this study, the effect of CF combined with its treat-
ment on the gut microbiota of 43 adults with CF was
investigated using high-throughput 454-pyrosequencing.
The results of this study demonstrated that the gut
microbiota of adults with CF is significantly altered rela-
tive to that of the non-CF control group. Gut microbiota
diversity also correlated with several clinical parameters,
most notably antibiotic exposure. This research on the
gut microbiota of CF adults is highly pertinent given the
change in the CF cohort age profile. As CF patients live
longer, there is a need to understand the impact that
long-term exposure to CF therapies, including antibi-
otics, have on an adult gut microbiota, with the future
aim of minimising any microbiota disturbances via
probiotic interventions, to achieve a gut microbiota
comparable with a healthy cohort.
Methods
Study participants
A total of 43 individuals with CF (25 males;18 females,
Mean age of all CF individuals, 29 ± 8.3 years; median
age, 27 years) were recruited during a period of stability
(no changes to their pulmonary status as determined by
their clinical team) from the Cork Adult Cystic Fibrosis
Centre, Cork University Hospital. No participants re-
ported acute or active gastrointestinal symptoms at the
time of sampling. One faecal sample was collected per
patient, upon visit to the CF clinic. Individuals who were
undergoing a pulmonary exacerbation (as determined by
their clinical team) at the time of sampling or those who
had received a lung transplant were excluded from the
study. A total of 69 non-CF volunteers (n = 49 males; 20
females, Mean age of all controls, 32 years ± 8.1 years;
median age, 30 years) were recruited from the greater
Cork area as a control group for comparison of their gut
microbiota, to that of individuals with CF. Non-CF volun-
teers were eligible for inclusion provided they were aged
20–80 years, reported no gastrointestinal illness at the
time of sampling, and had not received antibiotics within
the previous 6 months. This study was approved by the
Clinical Research Ethics Committee of the Cork Teaching
Hospitals (reference number ECM 4 (kk) 01/05/12). Writ-
ten informed consent was obtained from all subjects in ac-
cordance with local research ethics committee guidelines.
Pyrosequencing and bioinformatics
Metagenomic DNA was extracted from faecal samples
using the QIAamp DNA Stool Mini Kit, as per the manu-
facturer’s instructions (Qiagen, Crawley, West Sussex, UK)
with the addition of an initial bead-beating step (30s beating
followed by 30s on ice repeated for a total of 3 min using
3 mm, 1 mm and 0.1 mm zirconia/silica beads; Stratech
Scientific). Samples were prepared for compositional
sequencing by amplification of the V4 region (239 bp prod-
uct) of the 16S rRNA gene using universal 16S primers one
forward, i.e. F1 (5′ AYTGGGYDTAAAGNG), and a com-
bination of 4 reverse primers, R1 (5′ TACCRGGGTHTCT
AATCC), R2 (5′ TACCAGAGTATCTAATTC), R3 (5′
CTACDSRGGTMTCTAATC) and R4 (5′ TACNVGGGT
ATCTAATC) as described by Ribosomal Database Projects
(RDP) Pyrosequencing pipeline (http://pyro.cme.msu.edu/
pyro/help.jsp) [32, 33]. Samples were individually barcoded
to enable pooling of samples for sequencing and subse-
quent bioinformatic identification. Negative controls (where
UV treated PCR-grade water replaced DNA in the PCR
reactions) were included for all PCRs to ensure reactions
were free from contamination. The resulting amplicons
were sequenced using a Roche 454 GS FLX, at the Teagasc
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sequencing facility. Raw sequences were quality trimmed
using QIIME [34]. Reads with a minimum quality score of
25 and sequence lengths shorter than 150 bp for 16S rRNA
amplicon reads were removed. Trimmed FASTA sequences
were BLASTed against the SILVA 16S rRNA database (ver-
sion 106). The resulting BLAST outputs were parsed using
MEGAN [35], which assigns reads to NCBI taxonomies
using the Lowest Common Ancestor algorithm. A bit cut-
off score of 86 was used to filter the results prior to tree
construction. Phylum, family, and genus counts for each in-
dividual were extracted from MEGAN. Operational taxo-
nomic unit (OTU) assignment, chimera checking, clustering
and α (Chao1, Shannon diversity index, Simpson diversity
index and number of observed species tests) and β diversity
analysis (weighted and unweighted Unifrac) were imple-
mented with QIIME. Principal coordinate analysis (PCoA)
plots were visualised using EMPeror v0.9.3-dev.
Statistical analysis
Statistical analysis was performed on the sequencing
data using the non-parametric Kruskal-Wallis test in
Minitab Release 15.1.1.0 (Minitab Inc., 2007). Statistical
significances were accepted at p < 0.05, adjusted for ties.
Correlation analysis was completed using the Spearman
Rank correlation 2 tailed test using GraphPad Prism 5,
where significant correlations were accepted as p < 0.05.
Statistical analysis was performed to compare the results
between the CF patients and the controls. Additionally
we examined the impact of a number of clinical parame-
ters such as Clostridium difficile carriage, lung function
and antibiotic usage, on the CF gut microbiota.
Results
Gut microbiota analysis
Gut microbiota diversity analysis of individuals with CF
compared to non-CF controls
The gut microbiota of individuals with CF and non-CF con-
trols was investigated using high-throughput 16S rRNA
gene amplicon sequencing of faecal samples. A total of
2,099,804 reads were sequenced, corresponding to an aver-
age 23,331 reads/sample. Alpha and beta diversity analysis
was completed to determine the gut microbiota diversity of
the CF samples, compared to the non-CF controls.
The gut microbiota of those with CF was found to be sig-
nificantly (p < 0.05) less diverse compared to the non-CF
controls (Additional file 1: Figure S1). Principal coordinate
analysis plots generated using unweighted (A) and weighted
(B) Unifrac distance matrices showed that those with CF
clustered separately to non-CF controls (Fig. 1). However,
individuals with CF did not cluster based on carriage of
Clostridium difficile, class of CFTR mutation, % predicted
FEV1, pancreatic insufficiency, inpatient days or treatments
received i.e. proton pump inhibitors, courses of IV antibi-
otics and macrolide antibiotic therapy (data not shown).
This suggests CF and its associated therapy has a greater
combined effect on the diversity of the gut microbiota than
any individual treatment.
Gut microbiota composition of individuals with CF
compared to non-CF controls
Assigned sequence reads were used to assess differences in
taxonomic abundances between those with CF and healthy
controls at phylum, family, and genus levels. There was a
significant (p < 0.05) decrease in the relative abundance of
Bacteroidetes, Proteobacteria, Cyanobacteria,Verrucomicro-
bia, RF3, Tenericutes, and Lentisphaerae in individuals with
CF at the phylum level, relative to the non-CF controls
(Fig. 2). Notably, there were significant (p < 0.05) increases
in Firmicutes and Actinobacteria in people with CF relative
to the controls (47% vs. 39% respectively). At phylum level,
the CF gut microbiota was dominated by Actinobacteria
(48%) and Firmicutes (47%) compared to the non-CF con-
trols, in whom Bacteroidetes accounted for 39% of phyla
reads, compared to just 4% in the CF study group.
At the family level, a total of 21 families were present at
significantly altered proportions (p < 0.05) in those with CF
compared to non-CF controls; 14 families decreased includ-
ing, Alcaligenaceae, Prevotellaceae, Bifidobacteriaceae and
Fig. 1 Visualisation of the PCoA analysis based on unweighted (a) and weighted (b) Unifrac distance matrices. Samples separate into 2 clusters,
CF samples (red) and control samples (blue)
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Peptococcaceae (Fig. 3). At the genus level, significant differ-
ences in 42 genera were detected in those with CF com-
pared to non-CF controls (data not shown). This included
increased Enterococcus, Bacteroides, Leuconostoc and de-
creased Roseburia, Prevotella, Odoribacter, Faecalibacter-
ium and Bifidobacterium.
CF gut microbiota alterations based on clinical
parameters
The effect of duration of intravenous (IV) antibiotic
treatment on gut microbiota
To examine the effect of IV antibiotic treatment duration
on the gut microbiota, individuals with CF were divided
into no (n = 22), low (≤1; n = 9) intermediate (2–4; n = 8)
and high IV antibiotic treatment groups (≥5; n = 4) based
on the number of courses of IV antibiotics in the previous
year. The gut microbiota diversity of those with CF within
the low IV antibiotic group was significantly higher com-
pared to those in the intermediate or high IV antibiotic
groups (p < 0.05). At phylum level, individuals with CF in
the highest IV antibiotic group had the lowest Bacteroi-
detes and highest Firmicutes proportions of all CF individ-
uals (Fig. 4). Two families were significantly altered in
those with CF who were in the high IV antibiotic treat-
ment group,Veillonellaceae being highest in these individ-
uals and Helicobacteriaceae only being detected in the
Fig. 2 Percentage relative abundance of phyla in those with CF compared to non-CF controls
Fig. 3 Percentage relative abundance of the 21 families that were significantly different in the CF study cohort compared to the non-CF controls
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high IV antibiotic treated CF individuals. When the genera
were compared between the controls and the CF cohort
receiving 0, 1, 2–4 or ≥5 IV courses, it was evident that
those receiving the greatest number of IV courses had the
most altered gut microbiota compared to the non CF-
controls (Additional file 2: Figure S2).
To further investigate this, we performed correlation
analysis, the results of which indicated that a significant
negative correlation exists between the number of IV anti-
biotic courses and gut microbiota diversity (Fig. 5 a/c).
Alteration of gut microbiota with decreasing % predicted FEV1
Forced expiratory volume in 1 s (FEV1) is a measure of lung
function used to measure the progression of pulmonary
disease in people with CF. To assess whether the gut
microbiota changes with progression of lung disease in
those with CF, we compared the gut microbiota of the CF
study cohort who were stratified into having mild
(≥70%; n = 21), moderate (41–69%; n = 16) or severe
(≤40%; n = 6) lung disease [36, 37], based on their %
predicted FEV1. The gut microbiota diversity of individ-
uals was also correlated with % predicted FEV1 stratifi-
cations of mild, moderate or severe lung disease, with
the results indicating that a positive correlation exists
between gut microbiota diversity and % predicted FEV1
(Fig. 5 b/c). Individuals with CF who had severe lung
dysfunction (% predicted FEV1 ≤ 40%) had significantly
(p < 0.05) reduced α diversity relative to those with mild
or moderate lung dysfunction; those with mild lung dis-
ease (% predicted FEV1 ≥ 70%) had the highest α diversity
of all CF individuals studied (Fig. 5b). FEV1 levels appear
to have the greatest impact on overall gut α diversity,
rather than on any one bacterial population. When indi-
viduals with CF were stratified based on their % predicted
FEV1, no significant differences occurred at phylum or
family levels. Individuals with CF who had the highest %
predicted FEV1 had significantly increased Dorea, Pseudo-
butyrivibrio and Roseburia at the genus level compared to
those with moderate or severe lung disease (Fig. 6).
The effect of macrolide antibiotics on the gut microbiota of
people with cystic fibrosis
The effect of continuous prophylactic macrolide antibiotic
therapy on gut microbiota was investigated to determine
the impact that chronic maintenance antibiotic therapy had
on both the CF gut microbiota and overall diversity. Macro-
lide antibiotics had been used by 37 of the 43 individuals
with CF in this study in the 6 months prior to sample col-
lection. The composition of their gut microbiota was com-
pared to those who had not received these antibiotics in the
previous 6 months. Individuals receiving macrolide therapy
showed no significant differences in their gut microbiota
Fig. 4 Percentage relative abundance of phyla in the non-CF controls compared to the individuals with CF, stratified based on number of IV
courses in the previous 12 months
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diversity (based on α diversity analysis) relative to those who
had not received macrolide antibiotics. At the phylum level,
those receiving macrolide antibiotics showed significant (p <
0.05) decreases in Proteobacteria, Verrucomicrobia and
Eukaryota. At the family level Akkermansiaceae, Pasteur-
ellaceae, and Ruminococcaceae were all significantly re-
duced in those who received macrolides in the 6 months
prior to sample collection. These differences were also
evident at the genus level, with significant reductions in
the proportions of Bifidobacterium and Akkermansia evi-
dent in those who received macrolide antibiotics.
The effect of proton pump inhibitors on the gut microbiota
of people with cystic fibrosis
Proton pump inhibitors (PPI) are commonly prescribed
to individuals with CF to treat reflux symptoms. The
effect of PPIs on the gut microbiota of people with CF
was examined by comparing the gut microbiota of those
on PPIs (n = 20) to those not on PPI therapy (n = 23).
There was no significant (p > 0.05) difference in the gut
microbiota diversity or bacterial populations at phylum
or family levels in people with CF receiving PPI therapy,
relative to those not receiving PPIs. Significant decreases
in the proportions of Dialister and Subdoligranulum
occurred at the genus level in CF individuals receiving
PPI therapy, while Butyricoccus was only detected in
those receiving PPIs. Thus, the overall effects of PPIs on
gut microbiota were minimal.
Changes in the gut microbiota of pancreatic insufficient (PI)
CF individuals
PI is a common condition in people with CF. This study
examined the effect of PI on the gut microbiota of people
Fig. 6 Percentage relative abundance of significantly different genera in
the controls versus the individuals with CF stratified by % predicted FEV1.
Mild lung disease was classed as % predicted FEV1≥ 70%; moderate as
41–69% and severe ≤40%
Fig. 5 Correlation analysis of gut microbiota diversity and IV antibiotic courses (a Chao 1 and Simpson’s diversity index) and % predicted FEV1
(b Chao 1 and Simpson’s diversity index; 1 = FEV1 ≤ 40%, 2 = FEV1 41–69%, 3 = FEV1≥ 70%). Panel c provides the correlation coefficients and
p values for all diversity analysis
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with CF, by comparing the gut microbiota of those with
(n = 35) and without PI (n = 8), to determine if alterations
to digestion and the need for pancreatic enzyme replace-
ment therapies in cases of pancreatic insufficiency, would
impact on gut microbiota. Pancreatic sufficiency status
had been previously recorded for each participant as part
of routine CF care and these clinical data were made avail-
able for data analysis. No significant differences in diver-
sity or species richness were observed between pancreatic
insufficient and pancreatic sufficient CF individuals. At
the phylum level, Eukaryota were only detected in one in-
dividual who was pancreatic sufficient, but was not de-
tected in those who were insufficient. Ruminococcaceae
and Coriobacteriaceae were significantly decreased in pan-
creatic insufficient CF individuals compared to those who
were pancreatic sufficient. At the genus level, pancreatic
sufficient CF individuals had significantly (p < 0.05) in-
creased proportions of Ruminococcus and Anaerotruncus,
relative to pancreatic insufficient CF individuals.
Impact of cystic fibrosis conductance regulator class
mutation on the composition of the gut microbiota
CF is caused by a mutation in the CFTR gene which
codes for a chloride ion transport protein expressed at
epithelial cell surfaces. Mutations in the CFTR gene are
classified into 6 classes according to the mechanism by
which they disrupt the action of the CFTR protein. Class
1–3 mutations are considered the most severe as they
tend to result in a complete loss of function. To assess
the impact of CFTR mutations on gut microbiome com-
position, the gut microbiota of those with CFTR muta-
tions from classes 1–3 (n = 34) was compared to those
with less severe mutations (n = 9). No significant differ-
ences in species richness or microbial diversity were ob-
served between the CF cohort with class 1–3 mutations
and CF individuals with mutations from other classes.
People with CF with class 1–3 mutations had no signifi-
cant differences in the composition of their gut microbiota
at phylum level. At the family level, Enterococcaceae was
significantly (p < 0.05) increased, while Ruminococcaceae
was significantly (p < 0.05) decreased, relative to those
with less severe mutations. At the genus level, Subdoligra-
nulum, Paraprevotella, Anaerotruncus, and Barnesiella
were all significantly (p < 0.05) lower in those with severe
mutations (classes 1–3).
Alterations in the gut microbiota of CF individuals carrying
C. difficile
To assess whether alterations in the gut microbiota may pre-
dispose people with CF to colonisation with C. difficile, we
compared the gut microbiota of people with CF who were
asymptomatic carriers of C. difficile (n= 20), to those nega-
tive for C. difficile carriage (n = 13). C. difficile carriage was
determined as outlined in our previously published work
[38]. A non-significant (p > 0.05) reduction in microbial
diversity was observed in CF individuals carrying C. difficile.
Those positive for C. difficile carriage had a significant (p <
0.05) decrease in the proportions of Proteobacteria at the
phylum level relative to C. difficile free CF individuals. At
the family level, significant increases in Erysipelotrichaceae
Incertae Sedis were observed in CF individuals carrying C.
difficile. At the genus level, no significant differences oc-
curred between those carrying C. difficile and those free of
C. difficile.
Discussion
This study used high-throughput pyrosequencing of the
faecal microbiota of stable CF patients to investigate the
impact of CF on the gut microbiota compared to non-
CF controls. In addition, using clinical data, it was inves-
tigated whether certain parameters including class of CF
mutation, antibiotic exposure and FEV1 values were
associated with alterations to the gut microbiota in indi-
viduals with CF.
The intestinal microbiota of subjects with CF was
shown to be altered compared to that of healthy controls,
as evidenced by their separate clustering by PCoA. The
diversity of the gut microbiota of individuals with CF was
also significantly reduced compared to that of healthy
controls. This is a common finding of studies on CF gut
microbiota compared to controls [39, 40]. Indeed, it
appears from studies on children with CF that this
decrease in diversity occurs early in life for CF patients,
with diversity decreasing with age, with CF teenagers
having diversity levels similar to those seen in healthy
control infants (1 year) [39]. As CF patients live longer,
there will be an increased need to appreciate how this di-
versity decreases with age and how best to minimise this
decline, to maximise patient gut microbiota diversity.
The CF samples did not cluster distinctly based on muta-
tions, antibiotic exposure, % FEV1 or other clinical parame-
ters. Thus, while CF evidently affects overall gut microbiota
diversity, the main causative factor for this is unclear and
most likely it is due to multiple factors, including antibiotic
exposure, genotype etc. Additionally, alterations in the taxo-
nomic abundance were observed between the two groups at
the phylum, family and genus levels. For example, it was
notable that there was a decrease in Faecalibacterium, Rose-
buria and Bifidobacterium in those with CF compared to
the non-CF controls, as these bacteria are generally regarded
as markers for a healthy gut microbiota [41–45]. Such find-
ings support previous CF gut microbiota studies [46] includ-
ing recent work by Schippa et al. who also noted decreased
Faecalibacterium and Bifidobacterium in CF individuals
[47]. Indeed, several studies have shown a decrease in Bifido-
bacterium in CF patients compared to controls. A study
using a Phylochip approach found the relative abundance of
Bifidobacterium was decreased compared to controls [40].
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Additionally, that study also found that the majority of
changes to the gut microbiota in CF occurred within the Fir-
micutes and Actinobacteria phyla, which is consistent with
our findings. Decreases in the relative abundance of poten-
tially beneficial gut microbiota populations including Bifido-
bacterium, presents the opportunity to develop probiotics
for use in a CF population. Some initial studies using pro-
biotics in people with CF have shown promising results [10,
28, 29, 48]. These studies have shown probiotic use in CF
results in decreased pulmonary exacerbations, reduced hos-
pital admissions and beneficial alterations to the gut micro-
biota. A recent review highlighted the beneficial effects of
probiotics in CF, but also emphasises the requirement for
further work on mechanisms of action and the specific
strains and dosage required to be effective [49]. Despite our
study being unable to identify which factor or combination
of factors cause the altered gut microbiota in CF, under-
standing the alterations that occur in the CF gut microbiota
compared to healthy controls presents the opportunity to
investigate targeted therapeutic approaches.
A shift towards an increased Firmicutes to Bacterio-
detes ratio was observed in CF subjects relative to the
non-CF control group. Under nutrition in CF patients is
associated with poor clinical outcomes, therefore those
with CF are recommended to consume a diet high in fat
and protein [50]. Diets high in fat have been shown to
increase the Firmicutes to Bacteriodetes ratio in mice,
independent of obesity [51]. However, while diet may
play a role in the altered gut microbiota, it is unlikely
that diet alone accounted for the overall change in
microbiota. Due to a lack of dietary data in this study,
we could not interrogate this further, but it is a topic we
will investigate in future studies.
Another major factor that alters the gut microbiota is
chronic antibiotic exposure. CF individuals are frequently
exposed to macrolide therapy and IV antibiotics to treat
pulmonary exacerbations. We have demonstrated a
negative correlation between IV courses and gut micro-
biota diversity. Moreover, those receiving the greatest
exposure to IV antibiotics had the highest levels of
Firmicutes of all CF individuals studied. Interestingly,
studies investigating the consequences of short-term
antibiotic exposure on gut microbiota (completed in
faecal fermentation models, mice and humans) have re-
vealed a dominance of Proteobacteria [32, 33, 52].
Indeed, several studies of CF children have found an
increase in Proteobacteria compared to levels seen in
controls. Hoffman et al. found (using next-generation
sequencing) a correlation between the marked in-
creased abundance of E. coli and altered gut functio-
nality in CF children compared to controls [53, 54].
Previous studies using the Illumina MiSeq sequencing
platform to analyse the progression of the CF micro-
biota in children with CF found that the development
of the CF gut microbiota is altered compared to that of
healthy control children [39]. The study also noted de-
creased Faecalibacterium as was seen in our study, but
found that Escherichia/Shigella levels increased with in-
creasing age. Differences in levels of Proteobacteria
seen in several studies compared to ours likely reflect
the age of the subjects studied and the use of different
research methods. Given the chronic exposure of the
CF gut microbiota to antibiotics, findings of increased
Firmicutes rather than Proteobacteria dominance in CF
adults, perhaps demonstrates a state of microbiota
equilibrium in those with CF, which is not only altered
compared to healthy controls, but also compared to
those on short-term antibiotic therapy. It has been
demonstrated that repeated antibiotic therapy causes
the microbiota to return to an intermediate microbiota,
resembling the microbiota prior to exposure, while also
retaining some features associated with antibiotic treat-
ment [55, 56]. Studies examining how the CF gut
microbiota changes from periods of stability compared
to during pulmonary exacerbations (when antibiotic
therapy would be increased) are required. Additionally,
studies with longer follow up periods post-exacerbation
would provide insight into how the CF gut microbiota
recovers following intensive antibiotic exposure. We
also investigated the effects of macrolide antibiotics on
the gut microbiota of CF individuals and found that
macrolides reduced Bifidobacterium and Akkermansia.
These bacteria have been positively associated with gut
health [45, 57]. It is worth noting that the majority of
individuals with CF were receiving macrolide therapy in
the 6 months prior to the study and so this topic
should be further studied in a larger CF cohort to con-
firm such findings. However, the results suggest that
there is an opportunity to use concomitant probiotics
during antibiotic therapy to stimulate the growth of
beneficial bacteria in the gut.
This study did not utilise any culture-based ap-
proaches to confirm the sequencing-based results. Previ-
ously, studies have employed culture-based approaches
to investigate the airway microbiota in patients with CF
[58]. However, while culture-based approaches provided
insight into the lung microbiota in CF, the application of
next-generation sequencing technologies advanced our
appreciation of the complexity of this environment, in-
cluding the prevalence of strict anaerobic bacteria, such
as Veillonella, not previously associated with the lungs.
Future studies would benefit from combining culturing
and sequencing-based approaches to provide insight into
the viability of the bacteria detected via sequencing-
based approaches.
A positive correlation between % predicted FEV1 and
gut microbiota diversity was identified. This is the first
time that such a correlation has been reported. Percentage
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predicted FEV1 is used as a marker of lung function and
therefore is used to track lung disease progression. As lung
disease progresses, increased antibiotic exposure is almost
guaranteed and so a collateral decrease in gut microbiota
diversity is not surprising. However, identifying such a cor-
relation presents a potential opportunity to use % predicted
FEV1 as a marker, not only for lung function, but also as an
indicator of gut microbiota diversity. Using such informa-
tion could enable measures such as probiotic and/or pre-
biotic therapy to be applied to help minimise the decrease
in gut diversity, thereby minimising the associated negative
health effects.
Individuals with CF frequently suffer from PI, with >85%
of individuals with CF having PI at birth [15]. This results in
altered digestion, particularly a reduced ability to digest fats
and to absorb fat soluble vitamins. Surprisingly, our findings
indicated no significant effects of PI on gut microbiota diver-
sity compared to pancreatic sufficient subjects and changes
in relative abundance of bacterial taxa were minimal. Such
findings may suggest that the use of pancreatic enzyme ther-
apy in those with PI may help limit the effects of altered nu-
trient metabolism on gut microbiota diversity, thus
explaining why pancreatic sufficient and insufficient individ-
uals did not differ in terms of their gut microbiota diversity.
However, as only 8 subjects were pancreatic sufficient, these
findings would need to be confirmed in a larger study with
greater statistical power. Additionally, this study noted that
neither the class of CFTR mutation, nor the use of proton
pump inhibitors affected the gut microbiota diversity. We
did note that those with more severe CFTR gene mutations
had significant changes in their gut microbiota compared to
those with mild mutations. Differences in gut microbiota
based on genotype have previously been shown, again dem-
onstrating that more severe mutations lead to greater
disturbances in the gut microbiota [47].
Despite C. difficile being considered an opportunistic gut
pathogen, which may proliferate following antibiotic therapy,
we did not observe a significant decrease in the gut micro-
biota diversity of those carrying C. difficile compared to
pathogen-free individuals. However, we know from a previ-
ous study performed with this cohort that 50% of people
with CF carry C. difficile in their stool and 63% (19/30) of
the isolates were toxigenic [38]. Interestingly, while toxin
was detected in the stool samples of those positive for C. dif-
ficile, none of these individuals reported any of the gastro-
intestinal symptoms normally associated with C. difficile,
suggesting that the CF gut protected these individuals from
developing C. difficile infection. Further studies are required
to understand the reasons for the high rate of asymptomatic
carriage of C. difficile in individuals with CF.
Conclusions
This is one of the largest single-centre, stable adult CF
cohort studies to date, to investigate the gut microbiota
of individuals with CF using next-generation sequencing
techniques. Additionally, we have interrogated their
associated clinical history and identified which clinical
aspects correlate to altered gut microbiota. We have
identified the correlation between % predicted FEV1 and
gut microbiota diversity, as well as specific bacterial pop-
ulations which are reduced in those with CF compared
to control subjects (many of which are associated with
gut health including Bifidobacterium and Akkermansia),
revealing an opportunity for targeted probiotic therapy.
These findings are important to help determine the po-
tential opportunities to minimise the disruption to the
CF gut microbiota that occurs due to disease and it's
management. Understanding the changes in an adult CF
population is also important as a large percentage of the
studies to date have been completed in children. How-
ever, people with CF are living longer, therefore there is
a greater need to understand the impact that chronic ex-
posure to CF therapeutics, most especially antibiotics,
has on the gut microbiota in an older CF population, as
described in this study. We acknowledge that our study
has certain limitations including an inability to investi-
gate the impact of diet on gut microbiota due to a lack
of dietary data. Additionally, individuals were only stud-
ied at one time point. Furthermore, we were unable to
separate the impact of several factors on the gut micro-
biota and as such our findings likely reflect the impact
of several factors in combination on the gut microbiota
of CF patients. Our aim is to conduct further studies to
interrogate the different effects (e.g. genotype, lung
disease severity, etc.) on gut microbiota in future studies.
Given the interesting findings from this study, further
studies will be conducted to investigate the gut micro-
biota of an even larger cohort of subjects with CF at dif-
ferent time points. As our appreciation of the role of CF
in the alteration of gut microbiota grows, the
requirement for further knowledge is essential towards
the development of new therapies to support treatment.
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